Goldman Sachs analyst Rajan Sharma notes that DBV Technologies (DBVT) stated In its most recent press release that there is substantial doubt regarding its ability to continue as going concern given available cash and cash equivalents is not projected to be sufficient to support its operating plan for at least the next 12 months. In light of this, the firm has suspended its investment rating, price target and earnings estimates for DBV Technologies with “insufficient information on which to base an investment view.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DBVT:
- Biotech Alert: Searches spiking for these stocks today
- DBV Technologies price target raised to $7 from $5 at H.C. Wainwright
- DBV Technologies announces positive regulatory updates for Viaskin peanut patch
- DBV Technologies jumps 80% to $1.26 after Viaskin regulatory update
- DBV Technologies completes patient screening for VITESSE trial